SkyePharma asthma drug wins European backing – Reuters UK

SkyePharma asthma drug wins European backing
Reuters UK
By Paul Sandle | LONDON (Reuters) – SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European
SkyePharma's asthma drug wins European backingLondon South East

all 4 news articles »

View full post on asthma – Google News

Train driver who took one in four days off sick wins £28000 unfair dismissal … – Daily Mail


Daily Mail

Train driver who took one in four days off sick wins £28000 unfair dismissal
Daily Mail
Darrin Thomas was sacked by rail operators Southeastern after taking the huge number of sick days – more than one every four days – because of his asthma. The 45-year-old, who had smoked since the age of 15, was sacked for 'poor attendance' just a
Makes you sickie: Train driver fired for taking 134 sick days in 22 months Mirror.co.uk
£28K FOR TRAIN DRIVER SACKED OVER 134 SICKIESExpress.co.uk

all 4 news articles »

View full post on asthma – Google News

Johns Hopkins wins $8.5M to study asthma among blacks – Baltimore Business Journal

Johns Hopkins wins $8.5M to study asthma among blacks
Baltimore Business Journal
Johns Hopkins Medicine researchers have won a $9.5 million federal grant to study why asthma is more common among blacks. The four-year effort will study the genetic code of 1000 people of African descent, including men and women from Baltimore.
$9.5 Million Federal Grant to Support "Asthma Genome" Project with African Newswise (press release)
Researchers look to genetics to understand African American-asthma linkBaltimore Sun (blog)

all 4 news articles »

View full post on asthma – Google News

Pfizer wins right to challenge Prempro damages award; Asthma market flat until … – FiercePharma

Pfizer wins right to challenge Prempro damages award; Asthma market flat until
FiercePharma
Item > The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK)Singulair, Decision Resources concludes. Release > Teva Pharmaceutical Industries ($TEVA) won an appeals court's

View full post on asthma – Google News